Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIM-0705 in Impaired Glucose Tolerance or Abnormal HOMA-IR
NCT01364155Phase 2Unknown
- Sponsor
- Limerick BioPharma
- Start
- May 2011
- Primary completion
- Aug 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of quercetin-3'-o-phosphate in impaired glucose tolerance (IGT), insulin resistance (IR), sponsored by Limerick BioPharma. Status: unknown.
02
Drugs
quercetin-3'-o-phosphate
03
Conditions
impaired glucose tolerance (IGT)insulin resistance (IR)
Beyond the preview
Go deeper on NCT01364155.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01364155.